AMENDMENT OF NIAID SOLICITATION
"Management of Information Resources on Therapeutic Agents for HIV and Opportunistic Infections"

Solicitation Number:	RFP-NIH-NIAID-DAIDS-07-27
Amendment Number:	Two (2)
Amendment Issue Date:	Friday, December 8, 2006
Proposal Due Date:	**Tuesday, January 9, 2007 at 3:00 PM, Local Time**
Issued By:	Jill M. Johnson Contracting Officer NIAID, NIH, DHHS Office of Acquisitions, DEA 6700-B Rockledge Drive Room 3214, MSC 7612 Bethesda, Maryland 20892-7612
Point of Contact:	Jill M. Johnson, Contracting Officer E-mail: JMJohnson@niaid.nih.gov

This amendment provides answers to additional questions regarding the RFP and amends the RFP in various sections throughout the document. The proposal due date and time are unchanged from Amendment No. 1 and remains set at January 9, 2007 at 3:00 p.m., local time. Offerors must acknowledge receipt of this Amendment No. 2 by identifying this amendment number and date of the amendment on each copy of the offer submitted. Failure to receive your acknowledgement may result in the rejection of your offer. Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.

Questions and Answers (numbering continued from Amendment No. 1)

10. RFP Section M – Evaluation Factors for Award states that "technical factors are of paramount consideration in the award of the contract" and that "evaluation criteria are used by the Technical Evaluation Committee when reviewing Technical Proposals."

a. Will the Technical Evaluation Committee be composed entirely of government employees, outside consultant/reviewers, or both?

In assembling the Technical Evaluation Committee, NIAID will follow agency peer review regulations, which require that the majority of members are non-governmental experts. A limited number of Federal Government employees are allowed to serve on the committee.

b. Will the agency rely exclusively upon the Technical Evaluation Committee's review of Technical Proposals for scoring technical factors that are of paramount consideration in the award of the contract? If no, please describe the additional technical proposal review process to be followed in the award of the contract.

Yes. Please refer to SECTION L, Paragraph 2, Instructions to Offerors, paragraph a, General Instructions, subparagraph (10), Selection of Offerors, and SECTION M of the RFP.

c. Please describe the evaluation procedure to be utilized by the agency following submission of Final Proposal Revisions.

We will use procedures described in FAR 15.3, Source Selection and agency policy.

The following excerpt from the NIH Manual Issuance Chapter 6315-1 entitled, "Initiation, Review, Evaluation, and Award of Research & Development (R&D) Contracts" describes the evaluation process after receipt of Final Proposal Revisions:

"a. Final Evaluation/Recommendations

After receipt of FPRs, the CO and PO conduct a final evaluation of technical, cost/price, and other salient factors, assisted by a Source Selection Panel (SSP), as the IC deems necessary. The CO appoints the SSP, using recommendations from the PO.

The SSP's final evaluations must apply the same criteria for the final evaluations of the FPRs as those used in the initial technical evaluation of proposals, and any other factors announced in the RFP. New information obtained during discussions may provide sufficient justification to rescore proposals.

b. Contractor Selection

The SSP recommends in writing to the CO which source(s) it judges can perform the contract in a manner most advantageous to the Government, price and other factors considered as described in the RFP. The CO has statutory authority for award selection."

11. Please confirm that a Weekly Progress Report is due each and every week after the effective date of contract. In other words, when Semi-Annual Progress Reports and a Final Report are required, is there still a requirement to concurrently submit a Weekly Progress Report? (See RFP, Attachment 5, at 2)

Weekly Progress Reports are due every week of the contract except for the when the Final Report is due. The RFP will be modified to make this clarification.

12. RFP, Attachment 5, at 2-3, states that Biweekly Literature Surveillance Memos shall include a title page containing nine subsets of data. Referenced SOW paragraph 2b describes a requirement for only four subsets of data elements.

a. Please make available for viewing a recent Biweekly Literature Surveillance Memo with examples of links to online libraries and databases.

See Attachment 10.

b. Confirm whether a title page of nine subsets of data is required <u>for each citation</u>.

A title page is not required for each citation. The RFP will be modified to distinguish between items to be included in the title page vs. elements to be included in each citation. Attachments 4 and 5 will be modified accordingly.

13. RFP, Attachment 5, at 3 describes procedures to be followed by the contractor prior to publishing study results. How many scientific manuscripts and/or reports have been submitted for publication in the peer-reviewed literature and/or study results presented at relevant scientific meetings since 1990 by the incumbent contractor

under its current and prior contracts? Please provide a bibliographic citation for each such publication listing authors and their affiliation.

No scientific manuscripts and/or reports have been submitted for publication in the peer-reviewed literature and/or study results presented at relevant scientific meetings to date. The requested information does not exist and thus it cannot be provided.

14. RFP, Attachment 5, at 3 describes requirements for the contractor's initial transition plan due within 15 calendar days after contract award (on or about September 25, 2007). Please describe what is to be provided to the contractor on day 1 of the contract and on each subsequent day through the first 15 days after contract award. With respect to the above, please fully describe all equipment, databases, back-up tapes, hard discs, hardware and software, source code for all developed software, documentation, and licenses that are, or are likely or anticipated, to be transferred from the incumbent contractor.

As stated in the Statement of Work, Attachment 4, page 2, the requested information will be submitted by the incumbent to the Government and provided to the successor contractor upon contract award. The only information we can provide at this time is a list of the equipment that will be transferred from the incumbent contractor to the successor contractor which is included in Attachment 11, Government Property Schedule.

15. Contract award is stated as "on/about September 25, 2007." See RFP Amendment 1, at 3. The incumbent contract expires September 20, 2007.

a. Will the agency extend the contract of the incumbent contractor?

Yes, the Government does intend to extend the contract.

16. Under this RFP, the Contractor is to update chemical and biological databases with pertinent published literature and NIAID confidential data and information. RFP, Article B.1 at 4.

a. In what medium is confidential NIAID data to be provided to the Contractor?

Confidential biological testing data will be provided by third parties to the NIAID Project Officer (PO) in a hard copy report format or by email. The PO provides a copy of the same report in the same medium to the contractor.

b. Will NIAID confidential data provided to the Contractor be marked confidential?

No, the data will not be marked "confidential". However, the contractor will be bound by the confidentiality agreement described in Appendix C.

17. Please describe the relevance of Article H.11a. entitled Sharing of Model Organisms for Biomedical Research (RFP at 14) to the Statement of Work.

Article H.11, Obtaining and Disseminating Biomedical Research Resources, is hereby deleted in its entirety and subsequent Articles in Section H renumbered accordingly (H.11 through H.16).

18. With respect to Security Categories and Levels (RFP at 43), Confidentiality is marked Moderate, Integrity is marked Low, and Availability is marked Low. Please explain the rationale/basis for Overall being marked Moderate.

We have assigned the overall security level of the effort to be consistent with the highest security level of any of the three subcategories - Confidentiality, Integrity and Availability, as instructed by the NIAID Information Systems Security Officer.

19. The Co-infections Database is described as containing "propriety" information. RFP, Attachment 4 at 1. Is this a misstatement?

The word was misspelled. The word should be "proprietary".

20. RFP Amendment One (1) states that the Contractor will be given access to electronic Journals by NIH. Will the Contractor be given access to computerized data information systems such as Web of Science, CAS-ONLINE, CAS-SciFinder, DIALOG, MEDLINE, International Pharmaceutical Abstracts and full text U.S. and European patent databases?

Yes, with the exception of CAS-ONLINE and International Pharmaceutical Abstracts and full text U.S. and European patent databases.

21. For SOW Task 2, Literature Surveillance, will the agency at time of contract award identify the last update file screened by the incumbent contractor for each computerized data information system?

Yes, the Government will provide this information at time of contract award.

22. Under SOW Task 2, Literature Surveillance, the contractor is to provide hard copies of designated publications.

a. How many hard copy pages per year have been delivered to the Project Officer?

Over the last year, approximately 480 hard copy pages have been delivered to the Project Officer.

b. How many requests/year has the Project Officer made for hard copy?

Over the last year, approximately 120 requests have been made by the Project Officer.

23. Please identify all database software/hardware that the agency requires the contractor to utilize in carrying out the Statement of Work under this contract.

a. For each unique software package, identify manufacturer, software name, version, operating system it runs under, a brief description of its use or purpose in performing the Statement of Work, and whether or not it is to be government furnished property.

No unique software is required.

b. For each piece of unique hardware, identify manufacturer, hardware name, part number, relevant technical specifications, a brief description of its use or purpose in performing the Statement of Work, age, and whether or not it is to be government furnished property.

No unique hardware is required.

24. Technical Proposals reviewed by the Technical Evaluation Committee are to be judged solely on the written materials provided by the Offeror. With respect to the phrase "to determine the validity and authenticity of the data," please describe the work to be performed and provide one or more concrete examples. As stated the quoted phrase is ambiguous, unclear, vague, and open to misinterpretation. Please note that "the data" has no antecedent reference. See CRITERION 2a, RFP at 54.

"The data" mentioned in the question refers to that which is being reviewed for abstraction from reports from laboratories and publications to be entered into databases.

25. Criterion 3, Project Management, sub-factor c. states: "Demonstrated organizational experience in computerized chemical databases management, maintenance, and quality control." RFP at 54.

a. Please confirm that the Technical Evaluation Committee's Technical Proposal review is limited solely to written materials provided by the Offeror describing its project management experience related to management, maintenance, and quality control of chemical databases.

The Technical Evaluation Committee's review is limited to the offeror's written technical proposal as stated in SECTION M of the RFP.

b. Please identify project management experience factors related to management, maintenance, and quality control that are unique to and limited only to chemical databases as opposed to bibliographic and data databases. If none, please consider making this sub-factor less restrictive.

We believe that demonstrated organizational experience in computerized chemical databases management, maintenance and quality control is an important criterion and is not restrictive for the purposes of this RFP. The offeror is expected to identify their organizational experience in computerized chemical databases management maintenance, and quality control.

c. To facilitate preparation of written materials that substantively address this sub-factor and to assist the Technical Evaluation Committee in its evaluation of Technical Proposals, please provide a scope note on what is (as opposed to what is not) a chemical database.

See the Overall Objectives and Scope in the Statement of Work, Attachment 4.

26. Criterion 4, Sub-criterion b states: "Information regarding ownership/lease of the facility which demonstrates availability for the duration of the proposed contract." RFP at 55.

a. Please state what information regarding facility ownership/lease is sufficient to achieve a perfect score with respect to this sub-factor.

The RFP is modified to delete paragraph b of Section M, Criterion 4, Facilities and Resources. In addition, Attachment 6, Appendix A, Section 5, Facilities and Resources, will be amended to delete the requirement for the offeror to provide lease or ownership information evidencing availability for the period of performance of the contract.

b. The seven (7) year period of performance start date is described in terms of "on or about." Please provide a date certain to ensure that ownership/lease of the facility demonstrates availability for the duration of the proposed contract.

On or about September 25, 2007 is the best estimate for the award of the contract.

c. We view this sub-factor as overly restrictive of competition and hence improper. Please consider revising.

As indicated above, this subfactor has been revised.

27. RFP, Attachment 3 at 1, states that a master database is "located and maintained at the incumbent contractor's site." Please confirm that that is the case and that the master database is not located and maintained on the site of the incumbent contractor's Web site host provider.

The master database is located and maintained at the incumbent contractor's site.

28. With respect to SOW Task 2a, please identify "other NIAID preferred protocol." RFP, Attachment 4 at 2.

The contractor will be advised by the Government after award of the contract of "other NIAID preferred protocols" as they become known.

29. With respect to SOW Task 2, when will the incumbent contractor cease its literature surveillance activity?

We anticipate that the incumbent will cease its literature surveillance activity on the last day of the contract.

30. Under SOW Task 3, "[T]he Contractor shall identify and abstract relevant chemical and biological information … from the public literature and from HIV and co-infections data reports from DAIDS-supported screening contractors …" RFP, Attachment 4 at 3.

a. Please provide several examples of abstraction of data covering the range of public literature and data reports.

Examples of chemical data abstracted include structure, chemical name, molecular formula and molecular weight. Examples of biological data abstracted include inhibition data, such as enzyme and cellular inhibition data, and in vitro animal model efficacy data.

b. Provide a detailed protocol of any required specifications/format for the abstraction of data.

See Attachment 4, Statement of Work, Paragraph 3c, for the format for the abstraction of data.

c. To abstract is to summarize or condense. The SOW description appears to require data extraction rather than data abstraction. Please confirm whether or not that is the case and if so correct the RFP SOW text.

We believe "abstract" is the best term and choose not to change the language in the RFP.

d. Please provide several recent representative examples from the current contract where the incumbent Contractor has provided "critical expert opinion on the validity and authenticity of the identified relevant data."

In certain cases the incumbent contractor corrected inaccurate/incorrect chemical structures or information in some articles. We cannot provide examples because we do not keep this information.

e. Please clarify whether "public literature" is to be construed as limited to peer reviewed literature.

Yes, this is an accurate description of what we intend by the term "public literature".

f. Please provide clarification of terms "validity" and "authenticity" with respect to the requirement to "[E]xert a critical expert opinion on the validity and authenticity of the identified relevant data." Please describe in more detail the task to be performed.

Sometimes mistakes are found in publications. Scientific publications are complex and expertise is required to understand the publications in order to identify errors or inaccuracies in the data and to abstract the most important data. This is what is meant by validity and authenticity.

31. Please provide detailed screen shots with appropriate captions of the user interfaces for the HIV, OIs, TB, and microbicides databases. Screen shots should, at a minimum, display screens for data entry, editing, deleting, and any other required functions to be performed by the Contractor with respect to those databases. Any available drop down menus should be displayed and explained.

There are no standardized user interfaces for data entry, editing or deleting, the Anti-HIV, OIs, TB and Microbicides databases. MDL'S ISIS/BASE is the current user interface for accessing scientific information

contained in the Anti-HIV/OI/TB/Microbicide databases. Interfaces are created dynamically and are dependent on the specific activity.

32. Please make available for review all documentation related to use and maintenance of the HIV, OIs, TB and microbicides databases.

Documentation related to the use and maintenance (development, installation, update and maintenance activities) of the HIV, OI, TB and microbicides databases is the manufacturer-supplied (Oracle and MDL) user documentation provided by the software vendor. The Oracle documentation gateway site can be found at: http://www.oracle.com/pls/db901/db901.getting_started?remark=homepage
MDL documentation used for the use and maintenance of databases is available to MDL licensed users.

a. How often is documentation revised and/or updated?

Documentation is updated as needed.

b. When was documentation last revised and/or updated?

Database maintenance documentation was last updated on September 24, 2006.

c. Please make available a printout of the database record structure with explanation of all database fields.

See Attachment 12.

33. Please describe in technical detail the process by which open literature portions of the data fields from the HIV, OIs, TB, and microbicides databases are transferred to the publicly available Web database. See RFP, SOW Attachment 4 at 3.

The Government cannot provide this information because we do not possess such information. The offeror is expected to describe in their proposal under Technical Approach the technical details to meet the requirements of the Statement of Work.

34. The Contractor is required to maintain and update a literature citation database containing bibliographic data using ProCite software. RFP, Attachment 4 at 4.

a. Is ProCite software to be provided to the Contractor as government furnished property?

Yes.

b. Please provide several records representative of bibliographic data to be maintained and updated and describe the format of database fields, field delimiters, and record layout.

Below are several examples of bibliographic data that have been maintained and/or updated from time to time. Fields may include title, authors, journal, year, volume and page numbers. Fields can be delimited by commas, tabs or other delimiters of choice. There is no specific record layout. Not all fields listed will necessarily be populated.

Synthesis of substituted 1,3,4-oxadiazole, 1,3,4-thiadiazole and 1,2,4-triazole derivatives as potential antimicrobial agents

Vosooghi, M, Akbarzadeh, T, Fallah, A, Fazeli, MR, Jamalifar, H, and Shafiee, A Journal of Sciences, Islamic Republic of Iran 2005. 16(2): 145-151

2',3'-Dideoxynucleoside 5'-b,g-(Difluoromethylene) Triphosphates With a-P-Thio or a-P-Seleno Modifications: Synthesis and Their Inhibition of HIV-1 Reverse Transcriptase

Boyle, Nicholas, Fagan, Patrick, Brooks, Jennifer, Prhavc, Marija, Lambert, John, and Cook, PDanNucleosides, Nucleotides & Nucleic Acids 2005. 24(10-12): 1651-1664

PHI-443: A Novel Noncontraceptive Broad-Spectrum Anti- Human Immunodeficiency Virus Microbicide

D'Cruz, OJ, Samuel, P, and Uckun, FM

Biol Reprod 2004. 71(6): 2037-2047

c. Please make available for review all documentation and protocols for maintaining and updating the literature citation database.

The Government does not possess a protocol for maintaining and updating the literature citation database.

d. Please identify the specific version of ProCite software required to be utilized by the Contractor.

Attachment 9, Appendix D, Master Database, states "The chemical databases are currently managed using ISISTM/Base and ISIS/Host 4.0 (Window 2000 server/IIS5), ISIS/Direct 2.0, and ISIS/QSAR 2.2 software (MDL Information Systems, Inc., San Leandro, CA) for chemical structures. ORACLE and PROCITETM software version 5.0.3 (ISI, Philadelphia, PA) are utilized for data management and for the literature citations database."

e. ProCite is one of many commercially available software programs for managing and organizing bibliographic data and the FAR mandates that agencies avoid stating their needs/requirements in terms of brand name products. Please explain why the use of ProCite software is required to perform this task and explain why no other software product can satisfy the agency's requirement.

The Government has built the database using ProCite. We feel that continuation of use of this software is more economical than having to change the database to some other software.

35. SOW Task 4b requires the Contractor to maintain and update a PDF file as an Oracle table and link a specific citation "to the corresponding chemical structure and biological data in the HIV, OIs, TB, and microbicides database."

a. Please make available for review all documentation and protocols related to this task.

The Government does not possess protocols for updating and maintaining a PDF file as an Oracle table and linking a specific citation to the corresponding chemical structure and biological data in the HIV, OIs, TB, and microbicide databases.

b. Please provide a complete description of the Oracle table structure.

We cannot provide this information because a description of the Oracle table structure does not exist.

c. Please describe each specific step in the task to be performed and avoid making specific reference to features of name brand software (e.g., Oracle table).

The Government identifies, in general, the tasks to be accomplished. The offeror is expected to describe in their proposal under Technical Approach the technical details, including how they would accomplish the task

(including specific steps, if necessary), in performing tasks to meet the requirements of the Statement of Work.

36. SOW Task 4c requires the Contractor to transfer all biweekly literature citations in HTML format and with links to PubMed abstracts to the publicly available Web database. Please make available for review all documentation and protocols related to performing this task.

Documentation and protocols related to this task do not exist and thus we cannot provide this information.

37. SOW Task 4d requires that the Contractor deliver to the Project Officer within two business days after a request "hardcopies of reprints."

a. The use of the phrase "hardcopies of reprints" is unclear. As stated it appears that the agency is requesting the Contractor to make a photocopy of a publication offprint. Please clarify.

You are correct, the Contractor is to make a photocopy of a publication offprint.

b. The RFPs first mention of "reprint" is found in SOW Task 4d. Please describe all SOW details related to acquisition and processing of reprints under this contract.

All details are located in the Statement of Work, Task 4.d.

c. Please explain how all copies of reprints can be "located in the offices of DAIDS staff in Bethesda, Maryland" when the SOW only requires the Contractor to provide "hardcopies of reprints." As stated, this SOW requirement makes no sense.

We feel the requirement is stated clearly.

38. SOW Task 9a requires that the Contractor "provide and maintain" a "central facility for literature surveillance, abstracting of chemical and biological data, and updating of the databases."

a. The agency's "central facility" requirement is improper. It directs a Contractor to employ the business practices and specific methodology of the incumbent contractor (e.g., a central facility to perform literature surveillance, abstracting of chemical and biological data, and updating databases). Please consider removing this requirement.

The RFP has been amended to remove the words "central facility" and replace them with "facility or facilities".

b. The use of the term "abstracting" when applied to chemical and biological data is misleading and incorrect. Please revise.

We disagree with this statement. The RFP has not been revised.

39. SOW Task 9b requires that the Contractor provide and maintain facilities, equipment and resources including "[A]ll computer hardware and software, computer equipment and services."

a. Please provide examples of what is to be included under "computer hardware" as opposed to what is to be included under "computer equipment."

Computer equipment is all equipment used with a computer such as cables, speakers, wires, surge protectors, etc. Computer hardware includes such items as hard drives, monitors, and keyboards.

b. Please confirm that "services" are "resources" and provide an example of a service that the agency believes to be a "resource."

The RFP is amended to delete the word "services" from the SOW, Task 9b.

c. Please clarify and confirm whether "[A]ll" applies only to "computer hardware."

The RFP is amended to delete the word "all" from the SOW, Task 9b.

40. SOW Task 9c requires that the Contractor "provide and maintain" dedicated space for staff and equipment.

a. The agency again appears to be directing a Contractor to employ a specific business practice and methodology to carry out the SOW and this is improper. Please remove or revise this requirement.

We have not removed this requirement. We believe it is necessary for the Contractor to provide and maintain dedicated space for staff and equipment in order to carry out the work outlined in the SOW.

b. How many linear feet of file cabinet space will be needed for storage of data reports, reprints, and confidential information?

Approximately 10 to 15 linear feet of file cabinet space will be needed.

41. SOW Task 9d requires controlled access areas for secure storage of reprints. Please explain why reprints need to be housed in a controlled secure storage area.

This was an oversight. The RFP is amended to remove the word "reprints" from the SOW Task 9d.

42. In performing a Bibliographic Database Search from the public Web database that is hosted in Research Triangle Park, the following computer message was received:

"Active Server Pages error 'ASP 0113'

Script timed out

/struct_search/lr/LR_many.asp

The maximum amount of time for a script to execute was exceeded. You can change this limit by specifying a new value for the property Server.ScriptTimeout or by changing the value in the IIS administration tools."

In view of excessively slow search response times and unhelpful computer messages, please explain why this hardware/software system is not subject to change.

A large investment has been made by the Government in this system and is not subject to change.

43. SOW Task 5a requires the Contractor to maintain the availability of the public Web database without interruption by identifying and correcting problems in collaboration with NIAID OTIS staff. Please explain how the Contractor can be responsible for this activity without the authority to act on its own. Please consider revising this statement to read: Assist NIAID OTIS staff in maintaining the availability of the public Web database without interruption by identifying and correcting problems.

The RFP is amended to revise SOW Task 5a to read, "Assist NIAID OTIS staff in maintaining the availability of the public Web database without interruption by identifying and correcting problems."

44. SOW Task 5a refers to "Download" with respect to updates and computer programs. Please confirm that OTIS receives an email or disk from the Contractor of updates and computer programs it "Downloads" to the public Web database. Please confirm that "Download" rather than "Upload" is the correct term, and state how often a "Download" is performed by OTIS.

The RFP, SOW Task 5a, is amended to replace the word "download" with "upload". We confirm that OTIS receives both emails and disks from the Contractor of updates and computer programs it uploads to the Web. Uploading is performed on approximately a quarterly basis for the Web database.

45. For SOW Task 5b, please provide a description of the file data field format provided to OTIS by email or disk and provide the criteria used by the Contractor to determine non-confidential portions of the data fields from the HIV, OIs, TB and microbicides databases.

See answer to Question 32c for data field formats.

There are no confidential or non-confidential portions of data fields. The RFP is amended to revise the first sentence of Task 5b to read, "Update the Web database every three (3) months through the transfer of non-confidential data fields from the HIV, OIs, TB and microbicides databases."

46. For SOW Task 5c, please describe the procedures required to be used for linking compounds to other NIH literature or chemical databases.

The Government identifies, in general, the tasks to be accomplished. The offeror is expected to describe in their proposal under Technical Approach the technical details, including how they would accomplish the task in performing tasks to meet the requirements of the Statement of Work.

47. SOW Task 6a is unclear, vague, ambiguous, open to interpretation, and lacking in specific and required detail to permit an offeror (other than the incumbent contractor) to substantively respond. Please revise the specifications and descriptions for this task. In addition, please describe what specific hardware is to be maintained and describe existing procedures for computer update support, biweekly backups, and any and all security provisions to protect the confidentiality, integrity, and availability of the data.

We do not agree that Task 6a of the SOW is unclear. A list of equipment, including computer hardware is provided in response to question 14 above. There are no existing procedures for computer update, support, biweekly backups, and any and all security provisions to protect the confidentiality, integrity, and availability of the data, other than what is stated in the RFP.

48. In SOW Task 6a the agency once again improperly directs the Contractor to perform work using specific name brand software and fails to describe its requirements with any specificity other than database entry/editing/quality control, and management and maintenance of specific commercially available software packages. Please provide a more complete description of the agency's requirements conducive to competition.

We have named existing software and are unwilling to purchase new software. We can provide no further information.

49. SOW Task 6b is unclear, vague, ambiguous, open to interpretation, and lacking in specific and required detail to permit an offeror (other than the incumbent contractor) to substantively respond. Please revise the specifications and descriptions for this task. In addition, please describe, using historical data, what software development has occurred during prior contracts and make available for review documentation that was prepared for maintenance updates to fix bugs, improvements for security issues, or enhancements such as structured queries for the Oracle data.

Much of this type of work has been performed over the many years of the contract and is documented in the source code which will be provided to the successor contractor at the time of award. There is no requirement in the contract for the Contractor to describe how they did this, so we cannot provide this information.

50. SOW Task 6c is unclear, vague, ambiguous, open to interpretation, and lacking in specific and required detail to permit an offeror (other than the incumbent contractor) to substantively respond. Please revise the specifications and descriptions for this task. In addition, state how many onsite NIAID licenses are required for each specific software package.

We do not agree that SOW Task 6c is unclear and choose not to revise the specifications and descriptions. However, the RFP is amended to revise Task 6c to specify one copy of each license.

51. SOW Task 6d is unclear, vague, ambiguous, open to interpretation, and lacking in specific and required detail to permit an offeror (other than the incumbent contractor) to substantively respond. Please revise the specifications and descriptions for this task. The agency again fails to adequately state its requirements and inappropriately directs the Contractor in how it is to perform its work.

We do not agree that SOW Task 6d is unclear.

52. SOW Task 6e is unclear, vague, ambiguous, open to interpretation, and lacking in specific and required detail to permit an offeror (other than the incumbent contractor) to substantively respond. Please revise the specifications and descriptions for this task.

We do not agree that SOW Task 6e is unclear. This subtask is required by the Federal Information Security Management Act of 2002 (FISMA).

53. SOW Task 6f is unclear, vague, ambiguous, open to interpretation, and lacking in specific and required detail to permit an offeror (other than the incumbent contractor) to substantively respond. Please revise the specifications and descriptions for this task. In addition, please confirm that the publicly available Web database that will require onsite assistance is located in Research Triangle Park, North Carolina. Please state how often onsite assistance has been required in the past, the type of assistance that was required (e.g., hardware, software), the outcome or resolution, and the required time for response. Please make available for review the current NIAID Disaster Recovery Plan.

We do not agree that SOW Task 6f is unclear.

The publicly available Web database is not located in Research Triangle Park, North Carolina. It is located in Bethesda, Maryland.

Onsite assistance has never been required.

An NIAID Disaster Recovery Plan does not currently exist.

54. SOW Task 7 requires the Contractor, at the request of the Project Officer, to survey, retrieve, and assemble preclinical information on designated drugs or agents.

a. Historically, how many requests per year have been made to the Contractor?

This information is included in Appendix B, Additional Business Proposal Instructions, Page 2.

b. What formats, other than a written format, have been specified by the Project Officer?

This information is included in Appendix B, Additional Business Proposal Instructions, Page 2.

c. Please provide copies of preclinical information search request responses for review.

The following examples of search requests and responses are provided:

Example 1 – search request
"Please provide me with list of compounds that act as antagonists or inhibitors of mouse CCR5, if any, thanks."
Example 1 Response

aids no	CHEM NAME	EC50, ug/mL	IC50
211969	NH2-Met-Asp-Tyr-Gln-Val-Ser-Ser-Pro-Ile-Tyr-Asp-Ile-Asn-Tyr-Tyr-Thr-Ser-Glu-Pro-Cys-Gln-Lys-Ile-Asn-Val-Lys-COOH	> 50	50 ug/mL
211970	NH2-Ala-Ala-Ala-Gln-Trp-Asp-Phe-Gly-Asn-Thr-Met-Cys-COOH	30	N/A
211971	NH2-Arg-Ser-Gln-Lys-Glu-Gly-Leu-His-Tyr-Thr-Cys-Ser-Ser-His-Phe-Pro-Tyr-Ser-Gln-Tyr-Gln-Phe-Trp-Lys-COOH	15	50 ug/mL
211972	NH2-Gln-Glu-Phe-Phe-Gly-Leu-Asn-Asn-Cys-Ser-Ser-Ser-Asn-Arg-Leu-Asp-COOH	16	N/A
051947	SPYSSDTTPCCFAYIARPLPRAHIKEYFYTS GKCSNPAVVFVTRKNRQVCANPEKKWVRE YINSLEMS; RANTES (Human)	N/A	0.5 uM

Example 2 – search request
". . . to search for publications by Schotz, K from Schwabe (Germany) for compounds including peptides if any, thanks."

Example 2 response
PDF files on the two literature references below were transmitted to the requestor. Hard copies of two patents, US 20040137088A1 and MX PA0305657, were also delivered to the requestor.

Quantification of Allergenic Urushiols in Extracts of Gingo biloba Leaves, in Simple One-step Extracts and Refined Manufactured Material (EGb 761).
Schotz, K.. Phytochem Anal. 2004 15(1): 1-8.

Rutin is Essential for the Antidepressant Activity of Hypericum perforatum Extracts in the Forced Swimming Test. Noldner, M. and Schotz, K. Planta Med 2002 68(7): 577-580.

55. Literature Surveillance (SOW Task 2) requires the Contractor to "[D]escribe previous experience with the preparation of citation lists containing references related to the mission of DAIDS." RFP, Attachment 6 at 2. This requirement is overly restrictive of competition and improper in addition to being somewhat vague and unclear. In addition, the agency has failed to demonstrate that the phrase "related to the mission of DAIDS" is necessary with respect to the specific tasks to be accomplished. The stated requirement should be deleted, or restated in less restrictive language.

In response to this concern, the RFP is modified. The referenced statement found in Attachment 6, page 2, "APPENDIX A, Additional Technical Proposal Instructions" is revised to read as follows, "Describe previous experience with the preparation of scientific citation lists."

56. SOW Task 8a requirements for a Principal Investigator are vague and open to interpretation as stated. Please clarify the following qualification-related phrases and describe the extent of experience, training, expertise, and qualifications required for the Technical Evaluation Committee to assign a perfect score to the proposed staff member:

a. knowledge in the area of HIV and OI therapeutics research;

b. experience in using and maintaining software in the management of chemical and biological databases;

c. experience with extracting and prioritizing relevant information from the scientific literature on HIV and OI experimental therapies; and

d. experience with the administration and overall monitoring of information resource management projects.

We feel that the SOW Task 8a is clear and that we have provided a list of the knowledge and experience needed in order to carry out this work without being unduly descriptive. You may also want to refer to Attachment 6, Appendix A, Additional Technical Proposal Instructions, for pertinent information.

57. SOW Task 8b requirements for key scientific and professional staff are vague and open to interpretation as stated. Please clarify the following qualification-related phrases and describe the extent of experience, training, expertise, and qualifications required for the Technical Evaluation Committee to assign a perfect score to the proposed staff members:

a. appropriate knowledge, training, and experience in the area of HIV and OI therapeutics research;

b. experience with literature surveillance and on-line database searches; and

c. expertise in relational databases.

We feel we have described our requirements to the best of our ability without being overly restrictive and that the SOW Task 8b is clear. You may also want to refer to Attachment 6, Appendix A, Additional Technical Proposal Instructions, for pertinent information.

58. SOW Task 8c requirements for Data Entry and Information Technology staff are vague and open to interpretation as stated. Please clarify the following qualification-related phrases and describe the extent of experience, training, expertise, and qualifications required for the Technical Evaluation Committee to assign a perfect score to the proposed staff members:

a. training and experience in the entry of chemical structure and biological information into chemical and biological databases; and

b. training and expertise in database management, and hardware and software maintenance.

We feel we have provided a list of the training and experience needed in order to carry out this work without being unduly restrictive and that SOW Task 8c is not vague. You may also want to refer to Attachment 6, Appendix A, Additional Technical Proposal Instructions, for pertinent information.

59. Technical Evaluation Criterion 1a for Principal Investigator is vague, unclear, open to interpretation, subjective, and hence inappropriate for evaluators to use as evaluation criteria. RFP at 53. Please clarify, revise, and restate the following phrases in a more meaningful and less subjective manner with respect to the extent of experience, training, expertise, and qualifications required so that Technical Evaluation Committee members and offerors know what is required to achieve a perfect evaluation score for this member of the staff:

a. Adequacy and suitability of the documented education, training and availability of the Principal Investigator for planning, managing and directing the proposed activities including experience in administering a project of similar content and complexity;

b. familiarity with past and current research in the areas of HIV and co-infections, antivirals, antimicrobials, and microbiology; and

c. knowledge of computer science aspects of the database software/hardware to be utilized under this contract.

We feel we have described our requirements to the best of our ability without being overly restrictive. The solicitation is unchanged.

60. Technical Evaluation Criterion 1b for key scientific and professional staff are vague, unclear, open to interpretation, subjective, and hence inappropriate for use as evaluation criteria. RFP at 53-54. Please clarify, revise, and restate the following phrases in a more meaningful and less subjective manner with respect to the extent of experience, training, expertise, and qualifications required so that Technical Evaluation Committee members and offerors know what is required to achieve a perfect evaluation score for these staff members:

a. Adequacy and suitability of key scientific and professional staff with respect to their demonstrated qualifications, availability, experience, education and training;

b. familiarity with past and current research in the area of HIV and co-infections, antivirals, antimicrobials, microbiology, in vitro assays and animal models;

c. experience in conducting on-line literature searches in appropriate databases.

d. capability to function as a resource to DAIDS for advice on the computer science aspects of the database software and hardware to be utilized under this contract; and

e. expertise in relational databases.

We feel we have described our requirements to the best of our ability without being overly restrictive. The solicitation is unchanged

61. Technical Evaluation Criterion 1c for Data Entry and IT Personnel are inappropriate, vague, unclear, open to interpretation, unreasonably subjective, and hence improper for use as evaluation criteria. RFP at 54. Please clarify, revise, and restate the following phrases in a more meaningful and less subjective manner with respect to the extent of experience, training, expertise, and qualifications required so that Technical Evaluation Committee members and offerors know what is required to achieve a perfect evaluation score for these staff members:

a. Adequacy, availability and suitability of training, qualifications and experience with respect to chemical structures and data entry;

b. quality control;

c. preparation of text and graphic data in html and gif format for Web site inclusion; and

d. database management, and using and maintaining hardware and software to be utilized under this contract; e.g., Molecular Design (MDL) and Oracle software.

Items b, c, and d are totally defective in that as stated they are meaningless for evaluation purposes; Item d is prejudicial and inappropriate as well with its reference to specific brand name software products.

We disagree. The solicitation has not been revised.

62. Technical Evaluation Criteria 2a, 2b, and 2c are inappropriate, vague, unclear, open to interpretation, unreasonably subjective, and hence improper for use by members of the Technical Evaluation Committee as evaluation criteria. Please clarify, revise, and restate the following phrases (Adequacy and feasibility (2a), Adequacy and appropriateness (2b), and Adequacy and feasibility (2c)) in a more meaningful and less subjective manner with respect to the extent of experience, training, expertise, and qualifications required so that Technical Evaluation Committee members and offerors know what is required to achieve a superior evaluation score for these criteria.

We disagree. The solicitation is unchanged.

63. Technical Evaluation Criteria 3a, 3b, 3c and 3d are inappropriate, vague, unclear, open to interpretation, unreasonably subjective, and hence improper for use by members of the Technical Evaluation Committee as evaluation criteria. Please clarify, revise, and restate the following phrases (Adequacy and appropriateness (3a), Appropriateness and feasibility (3b), Demonstrated (3c) and Appropriateness and adequacy (3d)) in a more meaningful and less subjective manner with respect to the extent of experience, training, expertise, and qualifications required so that Technical Evaluation Committee members and offerors know what is required to achieve a superior evaluation score for these criteria.

We disagree. The solicitation has not been revised.

64. Technical Evaluation Criterion 4 is inappropriate, vague, unclear, open to interpretation, unreasonably subjective, and hence improper for use by members of the Technical Evaluation Committee as evaluation criteria. Please clarify, revise, and restate the phrase "Adequacy and availability of all necessary" so that Technical Evaluation Committee members and offerors know what is required to achieve a superior evaluation score for this criterion. Sub-factor 4b requiring demonstration of ownership/lease of the facility for the duration of the proposed contract is improper based on insufficient information in the RFP. Please delete.

We do not agree that Technical Evaluation Criterion 4 is vague with respect to the words "Adequacy and availability of all necessary…" The RFP is modified to delete paragraph b of Criterion 4, Facilities and Resources. In addition, Attachment 6, Appendix A, Section 5, Facilities and Resources, is amended to delete the requirement for the offeror to provide lease or ownership information evidencing availability for the period of performance of the contract.

65. Please state whether this contract deals with non-English language materials and if it does, please describe how such materials are handled since there does not appear to be any provision for foreign language capability stated in the requirements.

The contract deals with non-English language materials. This happens once or twice per year. However, the contractor is not required to translate the materials.

End of Questions and Answers

SECTION H – SPECIAL CONTRACT REQUIREMENTS

Article H.11, Obtaining and Disseminating Biomedical Research Resources, is hereby deleted in its entirety and subsequent Articles in Section H renumbered accordingly (H.11 through H.16).

SECTION J – LIST OF ATTACHMENTS

The following are added to the list of attachments:

Attachment No.	Title	Location
Attachment 10	Sample Biweekly Literature Surveillance Memo	End of Amendment 2
Attachment 11	Government Property Schedule	End of Amendment 2
Attachment 12	Database Record Structure	End of Amendment 2

SECTION M – EVALUATION FACTORS FOR AWARD

CRITERION 4 – FACILITIES AND RESOURCES, paragraph b, is deleted in its entirety.

Attachment 4, Statement of Work

Task 2, Literature Surveillance, paragraph b), is amended to read as follows:

b) Within fourteen (14) calendar days after contract award, provide the Project Officer with the first bi-weekly Literature Surveillance Memos containing literature citations for bHIV and OIs of potentially relevant published research works identified in paragraph 2a. Subsequent biweekly Literature Surveillance Memos, containing an average of 90 literature citations, shall be provided to the Project Officer every two weeks over the contract's period of performance. Bi-weekly Literature Surveillance Memos shall be provided as hard copies and electronic files with links to online libraries and databases. The Biweekly Literature Surveillance Memos shall include the following elements:

A title page which includes: 1) Contract number and title; 2) Type of literature report, HIV or OIs; 3) Period of performance being reported; 4) Contractor's name and address; and, 5) A brief introduction describing the subject list, and

A list of citations which includes the following for each citation: 1) database used to generate the citation; 2) citation title; 3) citation author(s), and 4) journal or patent number and date of publication.

Within five (5) business days of receipt of the bi-weekly Literature Surveillance Memos, the Project Officer will review the literature citations, and provide the Contractor with a subset for abstracting. An average of 70 citations for abstracting is anticipated on a monthly basis.

Task 5, Maintenance of the Publicly Available Web Database, paragraphs a) and b) are amended to read as follows:

a) Assist NIAID Office of Technology Information Systems (OTIS) staff in maintaining the availability of the public Web database without interruption by identifying and correcting problems. Upload of all updates and computer programs from the Contractor to the publicly available database server will be performed by OTIS staff.

b) Update the Web database every three (3) months through the transfer of non-confidential data fields from the HIV, OIs, TB and microbicides databases. Update the web database biweekly with literature citations described in paragraph 2.b). All updates shall be provided to the assigned OTIS staff responsible for the upload through e-mail or computer disc. The contents of the Web database are available on the website http://chemdb.niaid.nih.gov.

Task 6, Software/Hardware Maintenance, Development and Provision of Security, paragraph c) is amended to specify one copy of each license to read as follows:

c) Provide NIAID with onsite media and **one license each** for all required software (e.g. MDL ISIS, Oracle, etc.), documentation and source code of all developed software. All computer software, documentation and deliverables shall be the property of the U.S. Government.

Task 9, Facilities, Equipment and Other Resources

Paragraph a) is amended to remove the words "central facility" and replace with "facility or facilities" to read as follows:

a) A facility or facilities for literature surveillance, abstracting of chemical and biological data, ad updating of the databases.

Paragraph b) is amended to delete the words "all" and "and services" to read as follows:

b) Computer hardware and software and computer equipment.

Paragraph d) is amended to remove the word "reprints" to read as follows:

c) Controlled access areas for secure storage of data reports and confidential information.

Attachment 5, Reporting Requirements and Other Deliverables

On the chart under Paragraph B, Technical Reports Delivery Schedule, the first row is amended to read as follows:

Type of Deliverable	Initial Report Due	Recipients and Copies	Subsequent Reports Due
Weekly Progress Reports	1 week after effective date of contract	1 electronic copy – PO, CO	Weekly, due no later than each Monday. **No Weekly Progress Report is due when the Final Report is due.**

Paragraph C, Other Reports/Deliverables, 1. Biweekly Literature Surveillance Memos, is amended to read as follows:

As referenced in SOW paragraph 2b, prepare and submit to the Project Officer Biweekly Literature Surveillance Memos that include citation lists for both HIV and OIs of potentially relevant published research works. The Biweekly Literature Surveillance Memos shall include the following elements:

A title page which includes:

(1) Contract number and title
(2) Type of literature report, HIV or OIs
(3) Period of performance being reported
(4) Contractor's name and address
(5) A brief introduction describing the subject list

And a list of citations which include the following for each citation:

(1) Database used to generate the citation
(2) Citation title

(3) Citation author(s)
(4) Journal or patent and Date of publication

Attachment 6, Appendix A, Additional Technical Proposal Instructions

SECTION 3 – TECHNICAL APPROACH – the paragraph entitled Literature Surveillance (SOW Task 2) is amended to read as follows:

Provide a plan/technical approach to survey a broad base of literature sources and for selection of citations that contain chemical and biological information on experimental therapies for HIV and OIs. Describe previous experience with the preparation of **scientific citation lists.**

SECTION 5 – FACILITIES AND RESOURCES, paragraph a. is amended to read as follows:

a. a description of the location and features of the proposed facilities including a detailed floor plan and a list of equipment and resources dedicated to the project; and

END OF AMENDMENT #2 to RFP-NIH-NIAID-DAIDS-07-27

ATTACHMENT 10 – SAMPLE BIWEEKLY LITERATURE SURVEILLANCE MEMO

ONLINE DATABASE SEARCH - HIV-LS-361-MEMO

1. 59375 HIV-LS-361; PUBMED-HIV-11/13/2006
   Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
   Ji, L, Chen, FE, Xie, B, De, Clercq E, Balzarini, J, and Pannecouque, C
   Eur J Med Chem **2006**.
   HYPERLINK:

   http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17095124&dopt=abstract

2. 59376 HIV-LS-361; SCIFINDER-HIV-11/7/2006
   Preparation of bicyclic heterocycles, particularly pyrimido[2,1-c][1,4]oxazine-2-carboxamides, as HIV integrase inhibitors
   Naidu, BNarasimhulu, Banville, Jacques, Beaulieu, Francis, Connolly, Timothy P, Krystal, Mark R, Matiskella, John D, Ouellet, Carl, Plamondon, Serge, Remillard, Roger, Sorenson, Margaret E, Ueda, Yasutsugu, and Walker, Michael A
   PATENT: US **2006199956** ISSUE DATE: 20060907
   APPLICATION: 2005-26389 PP: 182pp., Cont.-in-part of U.S. Ser. No. 126,891.
   ASSIGNEE: (USA) ' ,
   HYPERLINK:

3. 59377 HIV-LS-361; SCIFINDER-HIV-11/7/2006
   Anti-HIV quinuclidine compounds
   Lecanu, Laurent, Greeson, Janet, and Papadopoulos, Vassilios
   PATENT: WO **2006085890** ISSUE DATE: 20060817
   APPLICATION: 2005 PP: 28pp.
   ASSIGNEE: (Samaritan Pharmaceuticals, Inc. USA and Georgetown University)
   HYPERLINK:

4. 59378 HIV-LS-361; PUBMED-HIV-11/13/2006
   Anti-HIV-1 Constituents from Leaves and Twigs of Cratoxylum arborescens
   Reutrakul, V, Chanakul, W, Pohmakotr, M, Jaipetch, T, Yoosook, C, Kasisit, J, Napaswat, C, Santisuk, T, Prabpai, S, Kongsaeree, P, and Tuchinda, P
   Planta Med **2006**.
   HYPERLINK:

   http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17091434&dopt=abstract

5. 59379 HIV-LS-361; PUBMED-HIV-11/13/2006
   Arylthiopyrrole (AThP) Derivatives as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: Synthesis, Structure-Activity Relationships, and Docking Studies (Part 2)
   Lavecchia, A, Costi, R, Artico, M, Miele, G, Novellino, E, Bergamini, A, Crespan, E, Maga, G, and Di, Santo R
   ChemMedChem **2006**.
   HYPERLINK:

   http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17089434&dopt=abstract

ATTACHMENT 11 – GOVERNMENT PROPERTY SCHEDULE

GOVERNMENT PROPERTY – SCHEDULE

3 Servers:

Dell Power Edge 4400
Dell Power Edge Server 2500 SC
Systemax 4 Server 988767 (Model SYSC-ST)

5 Desktop Computers:

Dell 2400
Dell 2400
Emachine t2885
Systemax Venture 105866826 (Model Venture B515)
Systemax Venture 105866827 (Model Venture B515)

Structure table and main data tables in NIAID master database.

1 AIDS_CHEM_MOLTABLE

Field Name	Type	No. of fields
		13
CDBREGNO	NUMBER(9)	
CTAB	BLOB	
MDATE	DATE	
MOLFORMULA	CLOB	
MOLWEIGHT	NUMBER	
AIDS_NO	CHAR(6)	
OI_NO	CHAR(6)	
HIV_NO	CHAR(6)	
SOURCE	VARCHAR2(500)	
SOURCE_ID	VARCHAR2(500)	
ENTRY_DATE	DATE	
UPDATE_DATE	DATE	
BOOLEAN_SALT	CHAR(1)	

2 OILIT

Field Name	Type	No. of fields
		124
AIDS#	CHAR(6)	
OI#	NUMBER(7)	
SALT_FORM	VARCHAR2(100)	
LITREF#	NUMBER(38)	
SOURCE	VARCHAR2(40)	
SOURCE_ID	VARCHAR2(150)	
OTHER_IDS	VARCHAR2(300)	
SECURITY	VARCHAR2(3)	
REPORT_DATE	VARCHAR2(15)	
REPORT_KIND	VARCHAR2(50)	
SUPPLIER	VARCHAR2(200)	
IVT_ORGANISM	VARCHAR2(150)	
IVT_STRAIN	VARCHAR2(250)	
ENZYME_SOURCE	VARCHAR2(50)	
ENZYME_NAME	VARCHAR2(150)	
ENZYME_TARGET	VARCHAR2(150)	
ENZYME_SUBSTRATE	VARCHAR2(75)	
ENZYME_TEST_KIND	VARCHAR2(100)	
ENZYME_TEST_METHOD	VARCHAR2(150)	
ENZYME_ACTIVITY	NUMBER(3)	
ENZYME_IC50_MOD	VARCHAR2(300)	
ENZYME_IC50	FLOAT(22)	
ENZ_COMPARISON_SOURCE	VARCHAR2(50)	
ENZ_COMPARISON_IC50_MOD	VARCHAR2(100)	
ENZ_COMPARISON_RESULT	FLOAT(22)	
ENZ_SI_METHOD	VARCHAR2(75)	
ENZYME_SEL_MOD	VARCHAR2(150)	
ENZYME_SEL	FLOAT(22)	

ENZYME_KI_MOD	VARCHAR2(150)
ENZYME_KI_RESULT	FLOAT(22)
ENZYME_CONC	FLOAT(22)
ENZYME_PCT_INHIB_MOD	VARCHAR2(150)
ENZYME_PCT_INHIB	FLOAT(22)
ENZYME_UNITS	VARCHAR2(50)
ENZYME_CONTROL_POS	VARCHAR2(150)
ENZYME_CONTROL_NEG	VARCHAR2(150)
ENZYME_COMMENTS	VARCHAR2(300)
CELL_LINE	VARCHAR2(100)
CYTOTOX_ACTIVITY	NUMBER(3)
CYTOTOX_DESCRIPTOR	VARCHAR2(200)
CYTOTOX_INHIB_CONC_MOD	VARCHAR2(300)
CYTOTOX_INHIB_CONC	FLOAT(22)
CYTOTOX_PCT_INHIB_MOD	VARCHAR2(300)
CYTOTOX_PCT_INHIB	FLOAT(22)
CYTOTOX_IC50_MOD	VARCHAR2(150)
CYTOTOX_IC50	FLOAT(22)
CYTOTOX_CONTROL_POS	VARCHAR2(150)
CYTOTOX_CONTROL_NEG	VARCHAR2(150)
IVT_TEST_ID	VARCHAR2(50)
IVT_TEST_KIND	VARCHAR2(75)
IVT_MIC_KIND	VARCHAR2(75)
IVT_MIC_METHOD	VARCHAR2(150)
IVT_MIC_DESCRIPTOR	VARCHAR2(250)
IVT_MIC_GTLT	VARCHAR2(6)
IVT_MIC_RESULT	FLOAT(22)
IVT_MIC_MOD	VARCHAR2(300)
IVT_ACTIVITY	NUMBER(3)
INHIB_METHOD	VARCHAR2(150)
INHIB_DESCRIPTOR	VARCHAR2(300)
INHIB_TARGET	VARCHAR2(150)
IVT_INHIB_CONC_MOD	VARCHAR2(150)
IVT_INHIB_CONC	FLOAT(22)
IVT_PCT_INHIB_GTLT	VARCHAR2(6)
IVT_PCT_INHIB	FLOAT(22)
IVT_PCT_INHIB_MOD	VARCHAR2(300)
IVT_IC_EC50_MOD	VARCHAR2(200)
IVT_IC_EC50	FLOAT(22)
IVT_UNITS	VARCHAR2(150)
IVT_SI_METHOD	VARCHAR2(150)
IVT_SI_MOD	VARCHAR2(50)
IVT_SI	FLOAT(22)
IVT_OTHER_ASSAY_KIND	VARCHAR2(100)
IVT_OTHER_CONC	FLOAT(22)
IVT_COMBO_CONC	VARCHAR2(50)
IVT_OTHER_CONC_UNIT	VARCHAR2(50)
IVT_OTHER_ASSAY_METHOD	VARCHAR2(200)
IVT_OTHER_ASSAY_DESCRIPTOR	VARCHAR2(300)
IVT_OTHER_ASSAY_ACTIVITY	NUMBER(3)
IVT_OTHER_RESULT_MOD	VARCHAR2(300)
IVT_OTHER_RESULT	FLOAT(22)
IVT_OTHER_UNITS	VARCHAR2(150)

IVT_POS_CONTROL	VARCHAR2(200)
IVT_POS_CONTROL_RESULT	VARCHAR2(300)
IVT_NEG_CONTROL	VARCHAR2(200)
IVT_NEG_CONTROL_RESULT	VARCHAR2(300)
IVT_COMMENTS	VARCHAR2(500)
IVV_ORGANISM	VARCHAR2(50)
IVV_STRAIN	VARCHAR2(150)
IVV_TEST_ID	VARCHAR2(30)
IVV_ACTIVITY	NUMBER(3)
DOSE	VARCHAR2(20)
UNIT	VARCHAR2(100)
ROUTE	VARCHAR2(100)
SCHEDULE	VARCHAR2(150)
DURATION	VARCHAR2(100)
EXP_DATE	VARCHAR2(50)
MODEL	VARCHAR2(100)
NUM_OF_ANIMALS	VARCHAR2(100)
IVV_PROTOCOL	VARCHAR2(200)
IVV_ASSAY	VARCHAR2(250)
IVV_ASSAY_DESCRIPTOR	VARCHAR2(250)
IVV_ASSAY_MOD	VARCHAR2(400)
IVV_ASSAY_RESULT	FLOAT(22)
IVV_UNITS	VARCHAR2(50)
IVV_TOX_TEST	VARCHAR2(150)
IVV_TOX_DOSE	VARCHAR2(50)
IVV_TOX_RESULT_MOD	VARCHAR2(150)
IVV_TOX_RESULT	FLOAT(22)
IVV_TOX_ACTIVITY	NUMBER(3)
AUC	VARCHAR2(75)
T_HALF_LIFE	VARCHAR2(75)
C_MAX	VARCHAR2(75)
PCT_ORAL_BIOAVAILABILITY	FLOAT(22)
TISSUE_DISTRIBUTION	VARCHAR2(30)
IVV_POS_CONTROL	VARCHAR2(200)
IVV_POS_CONTROL_RESULT	VARCHAR2(200)
IVV_NEG_CONTROL	VARCHAR2(200)
IVV_NEG_CONTROL_RESULT	VARCHAR2(200)
OBSERVATIONS_COMMENT	VARCHAR2(500)
ABSTRACTOR	VARCHAR2(15)
REVIEWER	VARCHAR2(15)
REVIEW_DATE	VARCHAR2(10)
LINE_ID	VARCHAR2(10)
SUM_ROW_ID	NUMBER(7)

3 HIV_LIT_IVT

Field Name	Type	No. of fields
HIV#	CHAR(10)	43
AIDS#	CHAR(6)	
LITREF#	NUMBER(10)	
SOURCE_ID	VARCHAR2(100)	
SALT_FORM	VARCHAR2(100)	
SUPPLIER	VARCHAR2(100)	

STRAIN_TYPE	VARCHAR2(200)
HIV_STRAIN_TYPE	VARCHAR2(400)
CELL_TYPE	VARCHAR2(200)
EC50_MOD	VARCHAR2(60)
EC50	FLOAT(22)
IC50_MOD	VARCHAR2(60)
IC50	FLOAT(22)
TI_MOD	VARCHAR2(60)
TI	FLOAT(22)
EC_PCT_CONC_MOD	VARCHAR2(60)
EC_PCT_CONC	FLOAT(22)
EC_PCT_MOD	VARCHAR2(60)
EC_PCT	FLOAT(22)
IC_PCT_CONC_MOD	VARCHAR2(60)
IC_PCT_CONC	FLOAT(22)
IC_PCT_MOD	VARCHAR2(60)
IC_PCT	FLOAT(22)
CONC_UNITS	VARCHAR2(20)
COMB_RAT	VARCHAR2(150)
COMB_EFF	VARCHAR2(300)
CONTROL	VARCHAR2(150)
ASSAY_METH	VARCHAR2(300)
TOX_ASSAY_METH	VARCHAR2(200)
TARGET	VARCHAR2(400)
MUTATIONS	VARCHAR2(300)
DRUG_SEL	VARCHAR2(200)
REL_RES_FOLD_INC_MOD	VARCHAR2(60)
REL_RES_FOLD_INC	FLOAT(22)
ACT_RATING	VARCHAR2(40)
COMMENTS	VARCHAR2(800)
CHEM_DATE	DATE
CHEMIST	VARCHAR2(20)
REVIEW_DATE	DATE
REVIEWER	VARCHAR2(20)
SECURITY	CHAR(1)
ROW_ID	NUMBER(10)
CELL_TYPE2	VARCHAR2(200)

4 **HIV_LIT_EI**

Name	Type	No. of fields
---	---	48
HIV#	CHAR(10)	
AIDS#	CHAR(6)	
LITREF#	NUMBER(10)	
SOURCE_ID	VARCHAR2(100)	
SALT_FORM	VARCHAR2(250)	
SUPPLIER	VARCHAR2(100)	
ENZYME_SOURCE	VARCHAR2(200)	
HIV_STRAIN_TYPE	VARCHAR2(100)	
ENZYME_GENERIC	VARCHAR2(200)	
ENZYME	VARCHAR2(200)	
IC50_MOD	VARCHAR2(100)	
IC50	FLOAT(22)	

IC50_CONC_UNIT	VARCHAR2(20)
KI_MOD	VARCHAR2(100)
KI	FLOAT(22)
KI_CONC_UNIT	VARCHAR2(40)
KM_MOD	VARCHAR2(100)
KM	FLOAT(22)
KI#KM_MOD	VARCHAR2(50)
KI#KM	FLOAT(22)
CONC_UNIT	VARCHAR2(100)
VMAX_MOD	VARCHAR2(100)
VMAX	FLOAT(22)
VMAX_UNITS	VARCHAR2(30)
KCAT#KM_MOD	VARCHAR2(40)
KCAT#KM	FLOAT(22)
KCAT#KM_UNIT	VARCHAR2(40)
INH_PCT_MOD	VARCHAR2(100)
INH_PCT	FLOAT(22)
INH_PCT_CONC_MOD	VARCHAR2(60)
INH_PCT_CONC	FLOAT(22)
INH_PCT_UNIT	VARCHAR2(100)
CONTROL	VARCHAR2(200)
SUBSTRATE	VARCHAR2(200)
ASSAY_METH	VARCHAR2(200)
TARGET	VARCHAR2(200)
MUTATION	VARCHAR2(200)
DRUG_SEL	VARCHAR2(200)
REL_RES_MOD	VARCHAR2(20)
REL_RES	FLOAT(22)
ACT_RATING	VARCHAR2(100)
COMMENTS	VARCHAR2(500)
CHEM_DATE	DATE
CHEMIST	VARCHAR2(10)
REV_DATE_DATE	DATE
REVIEWER	VARCHAR2(20)
SECURITY	CHAR(1)
ROW_ID	NUMBER(10)

5 **LITREF**

Name	Type	No. of fields
---	---	51
LITREF#	NUMBER	
PROCITE#	VARCHAR2(30)	
LSMEMO#	VARCHAR2(75)	
SOURCE	VARCHAR2(30)	
AUTHOR	VARCHAR2(600)	
TITLE	VARCHAR2(600)	
JOURNAL	VARCHAR2(500)	
VOLUME	VARCHAR2(80)	
PAGES	VARCHAR2(30)	
YEAR	VARCHAR2(20)	
DUPL	VARCHAR2(30)	
DATE_REQU	DATE	
DATE_RECD	DATE	

REQUESTOR	VARCHAR2(25)
NASR	CHAR(3)
CONTRACT	VARCHAR2(150)
SYN_DATA	VARCHAR2(10)
RESISTANCE	VARCHAR2(10)
PK_DATA	VARCHAR2(10)
PRIORITY	NUMBER
STATUS	VARCHAR2(200)
STR_ABSTR	VARCHAR2(10)
STR_DATE_OUT	DATE
STR_DATE_BACK	DATE
STR_NEW	NUMBER
STR_OLD	NUMBER
DATA_ABSTR	VARCHAR2(10)
DATA_DATE_OUT	DATE
DATA_DATE_BACK	DATE
DATA_IVT	NUMBER
DATA_IVV	NUMBER
DATA_HIV_EI	NUMBER
DATA_PK	NUMBER(5)
DATA_PHYS_PROP	NUMBER(5)
REVIEWER	VARCHAR2(10)
REVIEW_DATE	DATE
US_PAT_NO	VARCHAR2(100)
US_PAT_DATE	DATE
FOR_PAT_NO	VARCHAR2(100)
FOR_PAT_DATE	DATE
PCT_PUB_NO	VARCHAR2(100)
PCT_PUB_DATE	DATE
PAT_APPL_NO	VARCHAR2(100)
PAT_APPL_DATE	DATE
PAT_ASSIGNEE	VARCHAR2(450)
CAS_STR_COMP	VARCHAR2(10)
CAS_REF_COMP	VARCHAR2(10)
CAS_ACCES#	VARCHAR2(50)
MEDLINE_ACCES#	NUMBER(10)
PRIVATE_ACCESS	VARCHAR2(10)
KEYWORDS	VARCHAR2(400)

6 AIDSNAME

Name	Type	No. of fields
---	---	20
AIDS#	CHAR(6)	
CHEM_NAME	VARCHAR2(2000)	
ALT_NAME	VARCHAR2(2000)	
NSC#	VARCHAR2(150)	
CAS#	VARCHAR2(250)	
CLASS	VARCHAR2(500)	
STEXT	VARCHAR2(350)	
COMPANY	VARCHAR2(200)	
CHEMIST	CHAR(3)	
QCER	CHAR(3)	
CORP_ID	VARCHAR2(250)	

CONFID_NOTES	VARCHAR2(400)
LOG_P_EST	NUMBER(5,2)
ARB_NUM	VARCHAR2(100)
SEQUENCE	VARCHAR2(800)
PARENT_AIDS#	CHAR(6)
FDA_HIV_APPROVAL_DATE	DATE
FDA_HIV_CLINICAL_TRIALS	VARCHAR2(40)
TAACF_AACF_ID	VARCHAR2(1000)
TAACF_AACF_STANDARD	VARCHAR2(10)

Total number of fields 299